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Chronic treatment with long-acting nifedipine reduces
vasoconstriction to endothelin-1 in essential hypertension
Abstract
Essential hypertension is associated with enhanced biological activity of endothelin-1 (ET-1) and
impaired endothelium-dependent vasodilatation. Dihydropyridine calcium antagonists have antioxidant
activity in vitro, and they improve endothelial function in vivo. We tested whether calcium antagonists
also influence the biological activity of ET-1 in essential hypertensive (EH) patients in the presence and
absence of hypercholesterolemia. In 9 healthy subjects (normotensive [NT] subjects, age: 48.3+/-7.6
years; blood pressure: 118+/-8.6/69+/-5.4 mm Hg) and 21 EH subjects (age: 50.0+/-7.8 years; blood
pressure: 164.4+/-5.4/103.8+/-4.4 mm Hg), we studied forearm blood flow and its modification induced
by intrabrachial administration of ET-1, phenylephrine, acetylcholine, and sodium nitroprusside at
baseline and after 24 weeks of treatment with a nifedipine gastrointestinal therapeutic system (30 to 60
mg per day). At baseline, the first dose of ET-1 (0.5 microg/100 mL of forearm tissue per minute)
caused a slight vasodilatation in NT but not in EH subjects, whereas the following higher doses caused a
comparable dose-dependent vasoconstriction in EH and NT subjects. The effect of acetylcholine was
significantly reduced in EH as compared with NT subjects. In contrast, sodium nitroprusside and
phenylephrine had similar effects in NT and EH subjects. After chronic treatment with the nifedipine
gastrointestinal therapeutic system, the vasoconstrictor effect induced by both ET-1 and phenylephrine
was significantly blunted, whereas the response to acetylcholine was significantly increased and the
vasodilation to sodium nitroprusside unchanged. Hypercholesterolemic EH subjects showed a further
reduced response to acetylcholine compared with normocholesterolemic EH subjects, and the nifedipine
gastrointestinal therapeutic system restored the vasodilation to acetylcholine in this subgroup. In
conclusion, in EH subjects, chronic treatment with a long-acting dihydropyridine calcium antagonist not
only exhibits a blood pressure-lowering effect but also reduces ET-1-induced vasoconstriction and
improves endothelium-dependent vasodilation. Those vasculoprotective effects may importantly
contribute to a reduction in major clinical events seen during treatment with these compounds
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Abstract—Essential hypertension is associated with enhanced biological activity of endothelin-1 (ET-1) and impaired
endothelium-dependent vasodilatation. Dihydropyridine calcium antagonists have antioxidant activity in vitro, and they
improve endothelial function in vivo. We tested whether calcium antagonists also influence the biological activity of
ET-1 in essential hypertensive (EH) patients in the presence and absence of hypercholesterolemia. In 9 healthy subjects
(normotensive [NT] subjects, age: 48.37.6 years; blood pressure: 1188.6/695.4 mm Hg) and 21 EH subjects (age:
50.07.8 years; blood pressure: 164.45.4/103.84.4 mm Hg), we studied forearm blood flow and its modification
induced by intrabrachial administration of ET-1, phenylephrine, acetylcholine, and sodium nitroprusside at baseline and
after 24 weeks of treatment with a nifedipine gastrointestinal therapeutic system (30 to 60 mg per day). At baseline, the
first dose of ET-1 (0.5 g/100 mL of forearm tissue per minute) caused a slight vasodilatation in NT but not in EH
subjects, whereas the following higher doses caused a comparable dose-dependent vasoconstriction in EH and NT
subjects. The effect of acetylcholine was significantly reduced in EH as compared with NT subjects. In contrast, sodium
nitroprusside and phenylephrine had similar effects in NT and EH subjects. After chronic treatment with the nifedipine
gastrointestinal therapeutic system, the vasoconstrictor effect induced by both ET-1 and phenylephrine was significantly
blunted, whereas the response to acetylcholine was significantly increased and the vasodilation to sodium nitroprusside
unchanged. Hypercholesterolemic EH subjects showed a further reduced response to acetylcholine compared with
normocholesterolemic EH subjects, and the nifedipine gastrointestinal therapeutic system restored the vasodilation to
acetylcholine in this subgroup. In conclusion, in EH subjects, chronic treatment with a long-acting dihydropyridine
calcium antagonist not only exhibits a blood pressure–lowering effect but also reduces ET-1–induced vasoconstriction
and improves endothelium-dependent vasodilation. Those vasculoprotective effects may importantly contribute to a
reduction in major clinical events seen during treatment with these compounds. (Hypertension. 2007;49:285-290.)
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The endothelium plays a protective role for the vascularsystem, because it prevents the adhesion of circulating
blood cells, keeps the vasculature in a vasodilated state, and
inhibits the proliferation and migration of vascular smooth
muscle; NO and endothelin (ET)-1 reciprocally interact to exert
these effects. It has been documented that endothelial function is
impaired in essential hypertensive (EH) patients.1–6 Endothelial
dysfunction in EH patients seems to be characterized by a
reduction of NO bioavailability, as well as by an enhanced
biological activity of ET-1.7–9 These alterations could be in-
volved in the pathogenetic mechanism leading to the develop-
ment of atherosclerosis and to a rising in cardiovascular risk.10
Therefore, an important target for antihypertensive therapy
should be not only blood pressure reduction but also restoration
or at least improvement of endothelial function.
Dihydropyridine calcium antagonists do improve endothe-
lial function11–13 and, in an acute study, have also been shown
to reduce the vasoconstriction to exogenous ET-1.14 It is not
yet known whether such an effect is mediated by blood pres-
sure reduction alone or by some actions exerted by dihydro-
pyridine calcium antagonists.
Therefore, the present study tests the chronic effect of
dihydropiridine calcium antagonists on endothelial function
and, in particular, on the vasoconstriction induced by ET-1.
Moreover, we aimed to characterize the effect of that class of
antihypertensive drugs in reversing endothelial function in
hypertensive patients with and without hypercholesterolemia,
an additional risk factor for atherosclerosis.
Methods
Patients
The study population included 9 normotensive (NT) control sub-
jects and 21 matched EH patients. In accordance with institutional
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guidelines, the study was approved by the ethical committee of the
University of Pisa. All of the patients were aware of the investiga-
tional nature of the study and gave written consent. Any pharmaco-
logical treatment was discontinued 4 weeks before performing the
study. The demographic and clinical characteristics of the 2 groups
are shown in Table 1.
Essential hypertensive patients were recruited from among newly
diagnosed cases in our outpatient clinic if they reported that the
presence of a positive family history of essential hypertension and
supine arterial blood pressure (after 10 minutes of rest), measured by
mercury sphygmomanometer 3 times at weekly intervals, was
consistently found 140/90 mm Hg. Secondary forms of hyperten-
sion were excluded by routine diagnostic procedures. Because
hypercholesterolemia is also associated wit endothelial dysfunction,
the hypertensive study population was selected, taking into account
the lipid profile to, allow for evaluating the effect of nifedipine on
endothelial dysfunction in EH patients with or without high choles-
terol plasma values. Nine of the 21 patients had total plasma
cholesterol 240 mg/dL or low-density lipoprotein plasma choles-
terol 160 mg/dL.
Patients were enrolled if they were never treated (n9) or if they
reported a history of discontinued or ineffective pharmacological
antihypertensive treatment (n12). Among the latter subgroup, no
patient had been treated previously with a calcium antagonist.
Moreover, to avoid possible dropouts because of lack of blood
pressure normalization by nifedipine treatment, hypertensive patients
were tested for the response to the compound 4 weeks before
enrollment into the study. Blood pressure response to a single dose
of nifedipine (20 mg) was evaluated, and only those patients who
showed more than a 10% blood pressure decrease induced by drug
administration were finally enrolled. After this procedure, we screened
34 EH patients to select 21 patients who proved to be responders to
nifedipine treatment. The patients did not receive antihypertensive
drugs other than nifedipine during the time of the study and did not
report any use of other drugs. The NT subjects were matched for age
and sex to the hypertensive group, and they did not report any
pharmaceutical treatment.
Experimental Model
Forearm blood flow (FBF) studies were performed at 8:00 AM after
overnight fasting, with the subjects lying supine in a quiet, air-
conditioned room (22°C to 24°C). A polyethylene cannula (21-
gauge, Abbot) was inserted into the brachial artery under local
anesthesia (2% lidocaine). The cannula was connected through
stopcocks to a pressure transducer (model MS20, Electromedics) for
determination of systemic mean arterial blood pressure (one-third
pulse pressure plus diastolic pressure), heart rate (model VSM1,
Physiocontrol), and intra-arterial infusions. FBF was measured by
strain-gauge venous plethysmography (LOOSCO, GL LOOS). Cir-
culation to the hand was occluded 1 minute before each measurement
of FBF by inflating a pediatric cuff around the wrist at suprasystolic
blood pressure. Earlier work had determined the sensitivity and
reproducibility of the method.15 Forearm volume was determined by
the water-displacement method, and the drug infusion rate was
adjusted for each subject according to his or her forearm volume.
Thus, drug infusion rates were normalized to 100 mL of forearm
tissue by alteration of the drug concentration in the solvent. Drugs
used were infused through 3-way stopcocks at concentrations that
had no systemic effects.
Study Design
We evaluated the effect of a dose–response curve to intra-arterial
ET-1 (cumulative increase in infusion rates: 0.5, 25, and 50 g/100
mL of forearm tissue per minute for 5 minutes each dose) and to
phenylephrine (0.03, 0.1, 0.3, and 1 g/100 mL of forearm tissue per
minute for 5 minutes each dose). Endothelium-dependent forearm
vasodilation was evaluated by a dose–response curve to intra-arterial
acetylcholine (cumulative increase in infusion rates: 0.15, 0.45, 1.5,
4.5, and 15 g/100 mL of forearm tissue per minute for 5 minutes
each dose), whereas endothelium-independent vasodilation was as-
sessed by sodium nitroprusside (1, 2, and 4 g/100 mL of forearm
tissue per minute for 5 minutes each dose), a direct smooth muscle
cell relaxant compound.
The acetylcholine, sodium nitroprusside ,and phenylephrine
infusions were given in randomized sequence, and 30 minutes of
recovery was allowed between each experimental intervention.
Because of the long half-life, ET-1 was always tested as the last
infusion.
After the baseline FBF study, patients were given 30 mg of
nifedipine gastrointestinal therapeutic system (GITS) once daily for
4 weeks. After ensuring that no adverse clinical or biochemical
effects had occurred, the dose was increased to 60 mg once daily for
the remainder of the 20-week active treatment. Additional clinic
visits were scheduled every 4 weeks for the total duration of the
study. The FBF study was repeated 3 days (mean: 3.30.3) after
the end of the 24-week chronic active treatment.
Blood pressure measurements were performed in our outpatient
unit by a standard mercury sphygmomanometer. Blood pressure
values were determined as the mean of 3 measurements made at
2-minute intervals after the patients had been seated for 10 minutes.
Drugs
Acetylcholine HCl (Farmigea S.p.A.), ET-1 (Clinalfa AG), sodium
nitroprusside (Malesci), and phenylephrine (Farmigea S.p.A.) were
obtained from commercially available sources and diluted freshly to
the desired concentration by adding normal saline. Sodium nitro-
prusside was dissolved in glucosate solution and protected from light
by aluminum foil.
Data Analysis
Data were analyzed in terms of changes in FBF and forearm vascular
resistance (calculated as the ratio between intra-arterial mean pres-
sure and FBF and expressed as standard units). Because arterial
blood pressure did not change significantly during the FBF study,
increments in FBF were taken as evidence of local vasodilation as
decrements as evidence of local vasoconstriction. Differences be-
tween 2 means were compared by paired or unpaired Student’s t test,
as appropriate. Responses to acetylcholine, ET-1, phenylephrine, and
TABLE 1. Baseline Clinical Characteristics of the
Study Population
Clinical Parameters
NT
(n9)
HT Without
Hyperchol
(n12)
HT With
Hyperchol
(n9)
Age, y 48.37.6 49.88.6 50.76.7
Sex, male/female 7/1 11/1 9/0
BMI, kg/m2 23.21.4 27.62.6 25.82.8
Systolic BP, mm Hg 1188.6 165.36.1* 164.43.9*
Diastolic BP, mm Hg 695.4 102.94.5* 104.74.4*
Heart rate, bpm 56.54.1 65.74.9* 64.27.4
Glycemia, mg/dL 85.412.5 9511.5 91.09.2
Total cholesterol, mg/dL 178.125.2 191.626.5 263.124.5*†
HDL cholesterol, mg/dL 6319.2 46.813.1 38.77.7*†
LDL cholesterol, mg/dL 105.328 124.624.4 194.029.2*†
Triglycerides, mg/dL 49.321 101.048.6* 152.257.2*†
Smoking history, yes/no 0/8 0/12 0/9
Patients with diabetes mellitus, cardiac and/or cerebral ischemic vascular
disease, impaired renal function, and other major pathologies were excluded
from the study, as well as smokers (5 cigarettes per day). BMI indicates body
mass index; Hyperchol, hypercholesterolemia; BP, blood pressure; HDL,
high-density lipoprotein; LDL, low-density lipoprotein. Data are presented as
meanSD.
*P0.05 or less for NT vs hypertensive subjects.
†P0.05 or less for hypertensive patients with normal cholesterol vs
hypertensive patients with high cholesterol.
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sodium nitroprusside were analyzed by ANOVA for repeated mea-
sures. Wilcoxon’s test was used to check the statistical significance
of the difference between nonparametric values. Results were ex-
pressed as meanSD. Differences were considered statistically
significant at a value of P0.05. Computations for the statistical
method described were performed using the SAS System.
Results
The demographic, baseline hemodynamic, and humoral char-
acteristics for the NT subjects and EH patients are summa-
rized in Table 1. Age, sex, glycemia, and smoking history
were similar in both study groups and within the reference
range, whereas blood pressure differed (Table 1). Nine EH
patients had elevated plasma cholesterol values (Table 1).
Between the 2 latter subgroups, lipid profile was similar.
In EH patients, administration of nifedipine signifi-
cantly decreased blood pressure values from 164.45.4/
103.84.4 mm Hg to 126.99.5/81.22.4 mm Hg (P0.001
versus baseline) after 24 weeks of treatment. However, at the
time of the final FBF study, nifedipine had been withdrawn
for 3 days. Hence, blood pressure again increased up to
154.06.3/96.93.3 mm Hg (P0.001 versus active treat-
ment). Heart rate, body weight, lipid profile, and glucose
plasma levels were unchanged throughout the treatment
period (Table 2).
FBF Study
Basal Vascular Responses
The response to ET-1, phenylephrine, acetylcholine, and
sodium nitroprusside in EH patients and in NT subjects, in
terms of FBF and forearm vascular resistance, are reported in
Table 3. ET-1 caused a dose-dependent vasoconstriction,
which was comparable to the one obtained in NT controls
(Figure 1).
However, the response to the first dose of ET-1 causes a
slight vasodilatation in NT subjects but not in hypertensive
patients (FBF from 3.00.9 to 3.21.1 mL/100 mL forearm
tissue per minute in NT subjects versus 3.10.7 to 2.50.9
mL/100 mL forearm tissue per minute in hypertensive sub-
jects P0.021; Figure 1). Vasoconstrictor response to phen-
ylephrine resulted in similar responses in EH patients as
compared with NT controls (Figure 1). The dose-dependent
response to acetylcholine was significantly (P0.02) reduced
in EH patients as compared with NT subjects (Figure 2),
whereas the dose-dependent vasodilation to sodium nitro-
prusside was similar in both groups (data not shown).
The responses to sodium nitroprusside, phenylephrine,
and ET-1 were not significantly different in normocholester-
olemic and hypercholesterolemic hypertensive subgroups.
However, the response to acetylcholine was significantly
reduced (P0.032) in hypertensive subjects with high cho-
lesterol (FBF from 2.91.3 to a maximum of 140.4
mL/100 mL forearm tissue per minute; Figure 2) as compared
with hypertensive patients with normal cholesterol levels
(FBF from 2.91.0 to a maximum of 17.62.2 mL/100 mL
forearm tissue per minute; Figure 2). Contralateral FBF did
TABLE 2. Clinical Characteristics of the Hypertensive Patients
Included in the Study Before and After Treatment With
Nifedipine GITS
Clinical Parameters
HT (n21)
Before
Treatment
HT (n21)
After
Treatment
HT (n21) After
3-Day Therapy
Withdrawal
Systolic BP, mm Hg 164.45.4 126.99.5 154.06.3
Diastolic BP, mm Hg 103.84.4 81.22.4 96.93.3
Heart rate, bpm 65.06.0 63.54.6 69.17.8
Total cholesterol, mg/dL 222.244.1 217.041.7
HDL cholesterol, mg/dL 43.311.6 53.716.6
LDL cholesterol, mg/dL 121.955.9 124.768.4
Triglycerides, mg/dL 154.543.2 138.337.4
BP indicates blood pressure; HDL, high-density lipoprotein; LDL, low-density
lipoprotein. Data are presented as meanSD.
TABLE 3. Effect of 24-Week Treatment With Nifedipine GITS on FBF and Forearm Vascular Resistance in EH Patients and Baseline
Data Obtained in NT Subjects
Vascular Parameters
EH Patients
NT SubjectsBefore Treatment After Treatment
Baseline
Maximal
Doses Baseline
Maximal
Doses Baseline
Maximal
Doses
FBF, mL/100 mL forearm tissue per minute
ET-1 3.10.7 1.40.5 3.10.6 2.20.6† 3.00.9 1.30.5
Phenylephrine 3.20.8 1.40.4 3.10.8 2.10.6† 2.80.9 1.10.5
Acetylcholine 3.00.8 13.95.4* 2.90.8 21.86.6† 2.90.7 21.23.6
Sodium nitroprusside 2.80.9 15.76.5 2.90.8 14.46.1 2.70.8 16.34.0
Forearm vascular resistance, SU
ET-1 39.17.3 90.522.1 36.37.1 54.916.8† 287.6 56.215.2
Phenylephrine 39.07.5 89.922.8 38.47.8 56.316.1† 31.510.1 86.933.9
Acetylcholine 45.88.4 9.34.0* 40.28.8 5.41.5† 26.57.5 3.10.6
Sodium nitroprusside 43.97.3 8.63.6 39.78.2 8.63.0 31.18.6 5.21.7
FVR indicates forearm vascular resistance; SU standard unit.
*P0.05 or less for hypertensive patients vs NT subjects.
†P0.05 or less for before vs after treatment.
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not significantly change during the entire study (data not
shown).
Effect of Chronic (24-Week) Nifedipine
GITS Administration
Chronic nifedipine treatment lasted for 24 weeks and led to a
significant and persistent blood pressure reduction. At the end
of the treatment period, nifedipine was withdrawn for 3 days
before the final study. At that time, patients again became
hypertensive (Table 2).
The vasoconstrictor effect induced by both ET-1 and
phenylephrine was significantly blunted (P0.001) by treat-
ment with nifedipine GITS (Figure 1). Moreover, vascular
Figure 1. FBF responses (%) to ET-1
and phenylephrine in normotensive sub-
jects (n9, Œ), and hypertensive patients
(n21) before (●) and after (f) treatment
with nifedipine GITS. *P0.05 or less for
normotensive subjects vs hypertensive
patients; †P0.05 or less for hyperten-
sive patients before vs after treatment.
Figure 2. FBF responses to acetylcholine in normotensive subjects (n9, Œ) and hypertensive patients with normal (n9) cholesterol
(left) before (●) and after (f) treatment with nifedipine GITS and hypertensive patients with high cholesterol (n12; right), before ()
and after () treatment with nifedipine GITS. *P0.05 or less for normotensive subjects vs hypertensive patients; †P0.05 or less for
hypertensive patients before vs after treatment.
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responses to acetylcholine significantly increased (P0.001)
as compared with pretreatment values, whereas the vasodi-
lating effect of sodium nitroprusside was unchanged (Figure
2). This increase in acetylcholine-mediated vasodilation was
significantly more pronounced (P0.01) in hypertensive
patients with high cholesterol as compared with normocho-
lesterolemic hypertensive patients (Figure 2). Contralateral
FBF did not significantly change during the entire study (data
not shown).
Discussion
This study showed that, in hypertensive patients, a chronic
oral treatment with a long-acting dihydropiridine calcium
antagonist, nifedipine GITS, at clinically used dosages, re-
duces the vasoconstriction induced by ET-1 and phenyleph-
rine and improves the endothelium-dependent vasodilation.
This effect was seen after the treatment had been withdrawn
for 3 days in the presence of blood pressure values that were
similar to those at baseline. Therefore, this suggests that this
effect is unlikely because of the blood pressure reduction in
agreement with previous evidence demonstrating that blood
pressure normalization, per se, is not a maneuver sufficient to
increase endothelium-dependent vasodilation in the forearm
circulation of EH patients.2 Previous studies have shown that
blockade of ET-1 activity with endothelin receptor blockers
leads to an improvement in endothelium-dependent vasodi-
lation in patients with hypertension,16 suggesting that an
increased ET-1 activity may play a role in the pathophysiol-
ogy of this abnormality.
Previous data in human forearm circulation showed that
intra-arterial infusion but not oral administration of nifedipine
can reduce ET-induced vasoconstriction in NT subjects.14
The present study is the first demonstrating that oral admin-
istration of nifedipine, at clinically used dosages, is effective
in diminishing the vasoconstrictor effect of ET infusion in
hypertensive patients.
In EH patients, ET-1 only caused dose-dependent vasocon-
striction, which was found to be more pronounced, even if not
significantly different as compared with NT controls. How-
ever, as shown previously,14 the response to the first dose of
ET-1 caused a slight vasodilatation in NT subjects but not in
hypertensive patients suggesting a dysfunction of ET-
mediated endothelial-dependent vasodilation.
Because the mechanisms involved are known, as in certain
blood vessels, such as the porcine coronary artery, ET
receptors on vascular smooth muscle are linked to voltage-
operated Ca2 channels via G proteins.17 This may explain
why calcium antagonists reduce ET-induced vasoconstriction
in these vessels and are similarly effective in the human
coronary artery.18 In the human internal mammary artery, the
contractile effects induced by ET are mediated via a cascade
of activation of phospholipase C and diacylglycerol and,
ultimately, formation of inositol triphosphate, which, in turn,
releases Ca2 from the sarcoplasmic reticulum, thus increas-
ing cytosolic Ca2.19,20 In those vessels, calcium antagonists
do not markedly affect the response to ET.20
A nifedipine effect mediated by an interaction with intra-
cellular Ca2 handling is confirmed by the results obtained
with phenylephrine. Infusion of the adrenergic agonist in-
duced a dose-dependent vasoconstrictor response similar in EH
patients and in NT controls. After chronic nifedipine GITS
administration, the vasoconstrictor effect induced by phenyl-
ephrine was significantly blunted. This agrees with previous
evidence showing that nifedipine, as well as other calcium
antagonists, like diltiazem,21 amlodipine,22 verapamil,23 and
nitrendipine,23 reduced the vasoconstrictor effect of phenyleph-
rine21,22 or other -agonists, such as -methyl-nor-adrenaline.23
Another possible explanation might be related to a specific
effect of nifedipine on NO availability. Chronic treatment
with nifedipine GITS improved the vasodilation to acetylcho-
line but not that to sodium nitroprusside, confirming that
nifedipine improves endothelial function in hypertensive
patients. Previous data have shown that, in patients with
essential hypertension, an increase in acetylcholine-induced
vasodilation is related, at least in part, to an increased NO
bioavailability.24 Moreover, we demonstrated that nifedi-
pine increases endothelium-dependent vasodilation by re-
storing NO availability, an effect probably determined by
its antioxidant activity, because nifedipine decreased cir-
culating parameters of oxidative stress and prevented the
effect of the antioxidant vitamin C in patients with
essential hypertension.13
In NT subjects, where NO production is preserved, the
effect of ET-1 in maintaining vascular tone is very modest,
whereas in EH patients, where basal NO production is
reduced, a vasoconstrictor component of ET-1 seems to be
much more evident. Thus, the possibility exists that the
overall vascular effect of ET-1 on vascular tone is partially
dependent on the integrity of the NO pathway.9 Therefore,
nifedipine GITS by increasing NO bioavailability may play a
role in reducing the ET-1–mediated vasoconstriction.
The effect of nifedipine on acetylcholine-induced vasodi-
lation was more evident in hypercholesterolemic hyperten-
sive subjects, whereas no difference was observed concerning
the ET-mediated vasoconstriction between EH patients with
normal or high cholesterol. These data are in line with a
previous study, which showed that, in subjects without
advanced atherosclerosis, hypercholesterolemia is not associ-
ated with increased endogenous ET-1 activity above that
observed in the resistance vessels of healthy individuals,
whereas hypertension is characterized by increased ET-1
activity.25
Limitations of the Study
In this study we did not evaluate the mechanisms underlying
the effect of nifedipine GITS on endothelin-induced vasocon-
striction, but on the basis of previous data from our group,13
we may speculate that the increased NO bioavailability and
an antioxidative effect may have a role in the effect of
nifedipine on ET-induced vasoconstriction together with the
direct effect on intracellular Ca2 handling.18 Another limita-
tion of the study could be the fact that we selected patients in
which the blood pressure response to nifedipine GITS was
10%. This selection was done to be able to leave these
patients with a monotherapy for the whole study. The patients
excluded from the study were, therefore, patients who needed
to add another drug to nifedipine GITS to normalize their
blood pressure.
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Perspectives
These results suggest that nifedipine and possible calcium
antagonists not only lower blood pressure values but also can
have beneficial effects on vascular endothelium by reducing
ET-mediated vasoconstriction and increasing endothelium-
dependent vasodilation, thereby offering considerable poten-
tial in the prevention and/or treatment of atherosclerosis.
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